RVPH

0.313010.21%
JM

John M. Kane

Member of Advisory Board

Dr. John M. Kane, M.D is Member of Advisory Board of Terran Biosciences Inc. He serves as a Member of Clinical Advisory Board at MapLight Therapeutics, Inc. He serves as Chairman of Scientific Advisory Board of LB Pharmaceuticals Inc. He serves as Member of Scientific Advisory Board at Click Therapeutics, Inc. since March 2022. He served as Senior Vice President of Behavioral Health Services at Northwell Health, Inc until July 2023. He serves as the Chief Scientific Advisor at MedAvante, Inc. Dr. Kane serves as Vice President for Behavioral Health Services of North Shore - Long Island Jewish Health System, Inc. He is Chairman of the Department of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York as well as Professor and Chairman of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He is Chairman of Psychiatry and Professor of Psychiatry and Molecular Medicine at the Hofstra North Shore-LIJ School of Medicine. Dr. Kane has been the Principal investigator on numerous NIH and pharmaceutical industry sponsored clinical trials over years. He serves as Member of Clinical Advisory Board at Myriad RBM, Inc. (alternative name Rules-Based Medicine, Inc.). Dr. Kane has served on the Board of Scientific Counselors for the National Institute of Mental Health (NIMH), chaired the Psychopharmacologic Drugs Advisory Committee of the FDA and serves on the editorial boards of numerous journals. He serves as a Member of the Scientific Advisory Board at NuPathe, Inc. Dr. Kane serves as a Member of CNS Scientific Advisory Board of MedAvante, Inc. He serves as the President of the American Society of Clinical Psychopharmacology and the Schizophrenia International Research Society. He also serves as a Member of Advisory Board of The Chatham Institute. Dr. Kane also serves as a Professor of Psychiatry, Neurology and Neuroscience. Dr. Kane directs the NIMH-funded Intervention Research Center for the Study of Schizophrenia at The Zucker Hillside Hospital division of Long Island Jewish Medical Center. He serves as a Member of Medical Advisory Board at Intra-Cellular Therapies, Inc. and Reviva Pharmaceuticals, Inc. He is a Member of the Board of Scientific Counselors for NIMH. He serves as a Member of the Board of Directors of the American Society of Clinical Psychopharmacology and a Member of the Board of Trustees of the Association for Research in Nervous and Mental Disease. He served as a consultant to the Veterans Administration and the U. S. Department of Justice. Dr. Kane served as a consultant to numerous pharmaceutical companies on the topic of drug development and is on the editorial boards of several journals. He has published over 300 papers in scientific journals and is one of the most highly cited researchers in psychiatry. Dr. Kane is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Association Foundations' Fund Prize for Research, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State and the Dean Award from the American College of Psychiatrists. He is a Diplomate of the American Board of Psychiatry and Neurology. Dr. Kane is a board-certified clinician in psychiatry and neurology and has served as the Principal investigator for numerous research projects focusing on schizophrenia and psychobiology to improve the treatment, recovery and quality and cost of care. He holds B. A. from Cornell University and his M. D. from the New York University School of Medicine.

Positions